Acasti Pharma Inc reports results for the quarter ended in June - Earnings Summary

Reuters08-09

* Acasti Pharma Inc reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -46 cents. The lone analyst forecast for the quarter was for a loss of 34 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Acasti Pharma Inc's reported EPS for the quarter was a loss of 24 cents​.

* The company reported a quarterly loss of C$2.62 million.

* Acasti Pharma Inc shares had fallen by 16.4% this quarter and lost 15.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 6.3% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Acasti Pharma Inc is $6.00 This summary was machine generated from LSEG data August 9 at 02:21 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jun. 30 2024 -0.34 -0.37 Missed

Mar. 31 2024 -0.47 -0.18 Beat

Dec. 31 2023 -0.31 -0.30 Beat

-0.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment